纳美芬和纳洛酮治疗急性重度颅脑损伤的循证药物经济学评价

Evidence-based Pharmacoecomics Evaluation on Nalmefene and Naloxone in Treatment of Acute Severe Traumatic Brain Injury(ASTBI)

目的评价纳美芬与纳洛酮治疗急性重度颅脑损伤(ASTBI)的经济学效果。方法采用循证医学方法收集纳美芬与纳洛酮治疗急性重度颅脑损伤的临床随机对照研究,应用药物经济学的成本-效果分析法进行分析。结果纳美芬的有效率(84.0%)明显高于纳洛酮的有效率(72.0%,P=0.02);成本-效果比分别为67.15和5.01。结论从现有的证据来分析,在治疗急性重度颅脑损伤方面,纳洛酮比纳美芬更经济;但仍需进一步大样本、严格的随机对照研究加以验证。

OBJECTIVE To evaluate the cost-effectiveness of nalmefene and naloxone in the treatment of ASTBI.METHODS The Clinical data of nalmefene and naloxone from two papers about the treatment of ASTBI were collected by evidence-based medicine method and were evaluated with cost-effectiveness analysis.RESULTS The efficiency rates of nalmefene and naloxone in the treatment of ASTBI were 84.0%and 72.0%,and the corresponding cost-effectiveness were 67.15 and 5.01,respectively.CONCLUSION The cost-effectiveness of fluoxetine is superior to citalopram in the treatment of depressive disorders.